title: Vitamin K and hepatocellular carcinoma: The basic and clinic.
abstract: Vitamin K (VK), which was originally identified as a cofactor involved in the production of functional coagulation factors in the liver, has been shown to be involved in various aspects of physiological and pathological events, including bone metabolism, cardiovascular diseases and tumor biology. The mechanisms and roles of VK are gradually becoming clear. Several novel enzymes involved in the VK cycle were identified and have been shown to be linked to tumorigenesis. The VKs have been shown to suppress liver cancer cell growth through multiple signaling pathways via the transcription factors and protein kinases. A VK2 analog was applied to the chemoprevention of hepatocellular carcinoma (HCC) recurrence after curative therapy and was shown to have beneficial effects, both in the suppression of HCC recurrence and in patient survival. Although a large scale randomized control study failed to demonstrate the suppression of HCC recurrence, a meta-analysis suggested a beneficial effect on the long-term survival of HCC patients. However, the beneficial effects of VK administration alone were not sufficient to prevent or treat HCC in clinical settings. Thus its combination with other anti-cancer reagents and the development of more potent novel VK derivatives are the focus of ongoing research which seeks to achieve satisfactory therapeutic effects against HCC.
authors.affiliation: Xia Jinghe, Iwata Ozaki, Division of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, Saga 849-8501, Japan.
authors.forename: Xia
authors.initials: X
authors.lastname: Jinghe
authors.affiliation: Xia Jinghe, Iwata Ozaki, Division of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, Saga 849-8501, Japan.
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Mizuta
authors.affiliation: Xia Jinghe, Iwata Ozaki, Division of Hepatology, Diabetology and Endocrinology, Department of Internal Medicine, Saga Medical School, Saga University, Saga 849-8501, Japan.
authors.forename: Iwata
authors.initials: I
authors.lastname: Ozaki
keywords: Drug repositioning; Hepatocellular carcinoma; Nuclear factor-kappa B; Protein kinase A; Protein kinase C; Steroid and xenobiotic receptor; Vitamin K